Combination of diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance

Journal of Cancer

Volumn 5, Issue 3, 2014, Pages 173-181

  Li, Xin ^a   Guo, Yan Rong ^a   Lin, Jin Fang ^a   Feng, Yi ^a,b   Billig, Hakan ^b   Shao, Ruijin ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Endometrial carcinoma; Insulin resistance; PCOS; Progesterone resistance; Steroid hormone receptors

Indexed keywords

ANDROGEN; CYPROTERONE ACETATE PLUS ETHINYLESTRADIOL; FOLLITROPIN; INSULIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; METFORMIN; PIOGLITAZONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ANEMIA; ARTICLE; BODY MASS; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CURETTAGE; EARLY CANCER; ENDOMETRIAL THICKNESS; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENERGY EXPENDITURE; FEMALE; FEMALE FERTILITY; FOLLITROPIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYSTEROSCOPY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LUTEINIZING HORMONE BLOOD LEVEL; MENORRHAGIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGOMENORRHEA; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PHYSICAL ACTIVITY; TESTOSTERONE BLOOD LEVEL; TRANSVAGINAL ECHOGRAPHY; VAGINA BLEEDING; WITHDRAWAL BLEEDING;

EID: 84896991392     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.8009     Document Type: Article

References (53)

1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet, 2007, 370:685-697.
2. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med, 2005, 352:1223-1236.
3. Moran LJ, Hutchison SK, Norman RJ, Teede HJ. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev 2011;:CD007506.
4. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet, 2003, 361:1810-1812.
5. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online, 2009, 19:398-405.
6. Kim JJ, Kurita T, Bulun SE. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocr Rev, 2013, 34:130-162.
7. Lee WL, Lee FK, Su WH, Tsui KH, Kuo CD, Hsieh SL, Wang PH. Hormone therapy for younger patients with endometrial cancer. Taiwan J Obstet Gynecol, 2012, 51:495-505.
8. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod, 2012, 27:1327-1331.
9. Fearnley EJ, Marquart L, Spurdle AB, Weinstein P, Webb PM. Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study. Cancer Causes Control, 2010, 21:2303-2308.
10. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, et al. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol, 2011, 204:e351-357.
11. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev, 2002, 11:1531-1543.
12. Tong XM, Lin XN, Jiang HF, Jiang LY, Zhang SY, Liang FB. Fertility-preserving treatment and pregnancy outcomes in the early stage of endometrial carcinoma. Chin Med J (Engl), 2013, 126:2965-2971.
13. Shen ZQ, Zhu HT, Lin JF. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives. Obstet Gynecol, 2008, 112:465-467.
14. Session DR, Kalli KR, Tummon IS, Damario MA, Dumesic DA. Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent. Gynecol Endocrinol, 2003, 17:405-407.
15. Fauser BCJM. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod, 2004, 19:41-47.
16. Jing Z, Liang-Zhi X, Tai-Xiang W, Ying T, Yu-Jian J. The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. Gynecol Endocrinol, 2008, 24:590-600.
17. Odicino F, Pecorelli S, Zigliani L, Creasman WT. History of the FIGO cancer staging system. Int J Gynaecol Obstet, 2008, 101:205-210.
18. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol, 2007, 196:e401-410; discussion 402 e410-401.
19. Wheeler MJ. The determination of bio-available testosterone. Ann Clin Biochem, 1995, 32 ( Pt 4):345-357.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28:412-419.
21. Blackburn GL, Bistrian BR, Maini BS, Schlamm HT, Smith MF. Nutritional and metabolic assessment of the hospitalized patient. JPEN J Parenter Enteral Nutr, 1977, 1:11-22.
22. Shao R, Weijdegard B, Ljungstrom K, Friberg A, Zhu C, Wang X, Zhu Y, Fernandez-Rodriguez J, Egecioglu E, Rung E, Billig H. Nuclear progesterone receptor A and B isoforms in mouse fallopian tube and uterus: implications for expression, regulation, and cellular function. Am J Physiol Endocrinol Metab, 2006, 291:E59-72.
23. Shang K, Jia X, Qiao J, Kang J, Guan Y. Endometrial abnormality in women with polycystic ovary syndrome. Reprod Sci, 2012, 19:674-683.
24. Graham JD, Clarke CL. Physiological action of progesterone in target tissues. Endocr Rev, 1997, 18:502-519.
25. Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update, 2005, 11:277-291.
26. Rattanachaiyanont M, Angsuwathana S, Techatrisak K, Tanmahasamut P, Indhavivadhana S, Leerasiri P. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: a prospective study. J Obstet Gynaecol Res, 2005, 31:98-106.
27. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril, 2003, 80:1315-1324.
28. Aghajanova L, Velarde MC, Giudice LC. Altered gene expression profiling in endometrium: evidence for progesterone resistance. Semin Reprod Med, 2010, 28:51-58.
29. Shao R, Wang X, Weijdegard B, Norstrom A, Fernandez-Rodriguez J, Brannstrom M, Billig H. Coordinate regulation of heterogeneous nuclear ribonucleoprotein dynamics by steroid hormones in the human Fallopian tube and endometrium in vivo and in vitro. Am J Physiol Endocrinol Metab, 2012, 302:E1269-1282.
30. Wang HS, Chard T. IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. J Endocrinol, 1999, 161:1-13.
31. Lin J, Li R, Zhou J. The influence of insulin on secretion of IGF-I and IGFBP-I in cultures of human endometrial stromal cells. Chin Med J (Engl), 2003, 116:301-304.
32. Fowler DJ, Nicolaides KH, Miell JP. Insulin-like growth factor binding protein-1 (IGFBP-1): a multifunctional role in the human female reproductive tract. Hum Reprod Update, 2000, 6:495-504.
33. McCampbell AS, Broaddus RR, Loose DS, Davies PJ. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res, 2006, 12:6373-6378.
34. Fujimoto J, Nishigaki M, Hori M, Ichigo S, Itoh T, Tamaya T. Biological implications of estrogen and androgen effects on androgen receptor and its mRNA levels in human uterine endometrium. Gynecol Endocrinol, 1995, 9:149-155.
35. Fujimoto J, Nishigaki M, Hori M, Ichigo S, Morishita S, Tamaya T. Effects of Estradiol and Testosterone on the Synthesis, Expression and Degradation of Androgen Receptor in Human Uterine Endometrial Fibroblasts. J Biomed Sci, 1995, 2:160-165.
36. Slayden OD, Nayak NR, Burton KA, Chwalisz K, Cameron ST, Critchley HO, Baird DT, Brenner RM. Progesterone antagonists increase androgen receptor expression in the rhesus macaque and human endometrium. J Clin Endocrinol Metab, 2001, 86:2668-2679.
37. Palomba S, Falbo A, Zullo F, Orio F, Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev, 2009, 30:1-50.
38. Djiogue S, Nwabo Kamdje AH, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y, Seke Etet PF. Insulin resistance and cancer: the role of insulin and IGFs. Endocr Relat Cancer, 2013, 20:R1-R17.
39. Capp E, Jauckus J, von Eye Corleta H, Toth B, Strowitzki T, Germeyer A. Does metformin influence the insulin-, IGF I- and IGF II-receptor gene expression and Akt phosphorylation in human decidualized endometrial stromal cells? Eur J Obstet Gynecol Reprod Biol, 2011, 158:248-253.
40. Germeyer A, Jauckus J, Zorn M, Toth B, Capp E, Strowitzki T. Metformin modulates IL-8, IL-1beta, ICAM and IGFBP-1 expression in human endometrial stromal cells. Reprod Biomed Online, 2011, 22:327-334.
41. Giudice LC, Dsupin BA, Irwin JC. Steroid and peptide regulation of insulin-like growth factor-binding proteins secreted by human endometrial stromal cells is dependent on stromal differentiation. J Clin Endocrinol Metab, 1992, 75:1235-1241.
42. Zhai J, Liu CX, Tian ZR, Jiang QH, Sun YP. Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. Biol Reprod, 2012, 87:29.
43. Mioni R, Chiarelli S, Xamin N, Zuliani L, Granzotto M, Mozzanega B, Maffei P, Martini C, Blandamura S, Sicolo N, Vettor R. Evidence for the presence of glucose transporter 4 in the endometrium and its regulation in polycystic ovary syndrome patients. J Clin Endocrinol Metab, 2004, 89:4089-4096.
44. Nagamani M, Stuart CA. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol, 1998, 179:6-12.
45. Zhang G, Li X, Zhang L, Zhao L, Jiang J, Wang J, Wei L. The expression and role of hybrid insulin/insulin-like growth factor receptor type 1 in endometrial carcinoma cells. Cancer Genet Cytogenet, 2010, 200:140-148.
46. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle, 2010, 9:1057-1064.
47. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae-Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol, 2010, 116:92-98.
48. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, Bruchim I, Werner H. Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. PLoS One, 2013, 8:e61537.
49. Xie Y, Wang YL, Yu L, Hu Q, Ji L, Zhang Y, Liao QP. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Mol Biol, 2011, 126:113-120.
50. Dong L, Zhou Q, Zhang Z, Zhu Y, Duan T, Feng Y. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. J Obstet Gynaecol Res, 2012, 38:1077-1085.
51. Thomson RL, Buckley JD, Brinkworth GD. Exercise for the treatment and management of overweight women with polycystic ovary syndrome: a review of the literature. Obes Rev, 2011, 12:e202-210.
52. Carlson MJ, Thiel KW, Yang S, Leslie KK. Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer. Discov Med, 2012, 14:215-222.
53. Homburg R. Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol, 2004, 18:773-788.